Skip to main content

Aldesleukin Pregnancy and Breastfeeding Warnings

Brand names: Proleukin

Medically reviewed by Last updated on Feb 16, 2024.

Aldesleukin Pregnancy Warnings

This drug should be used during pregnancy only if the benefit outweighs the risk.

US FDA pregnancy category: C

-Sexually active women and men should use effective contraception during treatment.
-This drug should not be administered to fertile persons of either gender who are not practicing effective contraception.

Animal studies have revealed evidence of embryotoxicity. There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Aldesleukin Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

-Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during therapy.

See references

References for pregnancy information

  1. (2001) "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics

References for breastfeeding information

  1. (2001) "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.